Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Folic acid supplementation in children with sickle cell disease: a randomized double-blind noninferiority cross-over trial.

  • 2025-04
  • The American journal of clinical nutrition 121(4)
    • Brock A Williams
    • Heather McCartney
    • Joel Singer
    • Angela M Devlin
    • Suzanne Vercauteren
    • Ali Amid
    • John K Wu
    • Crystal D Karakochuk

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 31
Population
31 children with SCD, aged 2-19 y
Methods
double-blind randomized controlled noninferiority cross-over trial, 1 mg/d folic acid or placebo for 12 ± 1 wk, washout 12 ± 1 wk
Blinding
Double-blind
Duration
12 ± 1 wk

Background

Children with sickle cell disease (SCD) in Canada are routinely supplemented with folic acid to provide sufficient folate for the increased demands of erythropoiesis. However, with the mandatory folic acid fortification of refined grains and pharmacotherapies that extend the lifespan of sickled red blood cells (RBC), this clinical practice is in question.

Objectives

This study aims to determine the efficacy of folic acid supplementation by measuring the effect of 12 ± 1 wk of 1 mg/d folic acid, compared with placebo, on concentrations of RBC folate (primary outcome), serum folate, and 1-carbon-related metabolites, and clinical outcomes in children with SCD.

Methods

In this double-blind randomized controlled noninferiority cross-over trial, 31 children with SCD, aged 2-19 y, were enrolled and randomly assigned (1:1 with blocks of 4) to 1 mg/d folic acid, the current standard of care, or a placebo for 12 ± 1 wk. After a 12 ± 1 wk washout period, treatments were reversed.

Results

The mean [95% confidence interval (CI)] difference in endline RBC folate concentrations across treatments was -179 (-260, -99) nmol/L, with the lower boundary of the CI exceeding noninferiority but the upper boundary not (P = 0.0001; modified intention-to-treat). There was no significant difference in the number of participants who had RBC folate deficiency after each treatment (P = 0.059). No participants presented with serum folate deficiency (<7 nmol/L). There were no significant differences observed in 1-carbon metabolite concentrations (total homocysteine, S-adenosylhomocysteine, S-adenosylmethionine, vitamin B12, or methylmalonic acid), hematological measures, nor clinical outcomes (specifically acute pain episodes or megaloblastic changes) when individuals were supplemented with folic acid in comparison with placebo.

Conclusions

Despite mandatory food fortification and advances in the medical treatment of SCD, it appears that some children with this condition may still benefit from daily folic acid supplementation. Whether this translates to improved clinical outcomes remains uncertain. This trial was registered at clinicaltrials.gov as NCT04011345 (https://clinicaltrials.gov/study/NCT04011345).

Research Insights

  • Vitamin B9→Reduced Folate Deficiency

    There was no significant difference in the number of participants who had RBC folate deficiency after each treatment (P = 0.059).

    Effect
    Neutral
    Effect size
    Small
    Dose
    1 mg/d
  • Vitamin B9→Reduced Red Blood Cell Folate Concentration

    The mean [95% confidence interval (CI)] difference in endline RBC folate concentrations across treatments was -179 (-260, -99) nmol/L, with the lower boundary of the CI exceeding noninferiority but the upper boundary not (P = 0.0001; modified intention-to-treat).

    Effect
    Beneficial
    Effect size
    Small
    Dose
    1 mg/d
Back to top